# Institute for Follicular Lymphoma Innovation

> Institute for Follicular Lymphoma Innovation is a VC fund backing Biotechnology and Health Care. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 7
- Last investment: Aug 2025
- Lead investor: 71%
- Last updated: Aug 2026

Institute for Follicular Lymphoma Innovation is a VC fund focused on Biotechnology and Health Care. Follicular Lymphoma Innovation is an institute for bio-molecular innovations.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 86% |
| Health Care | 5 | 71% |
| Medical | 3 | 43% |
| Biopharma | 2 | 29% |
| Clinical Trials | 2 | 29% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 29% |
| Corporate Round | 2 | 29% |
| Seed | 1 | 14% |
| Post-IPO Equity | 1 | 14% |
| Venture - Series Unknown | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 43% |
| France | 2 | 29% |
| Switzerland | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CIT Therapeutics | CIT Therapeutics is a clinical-stage business company that develops new ways to treat unmet medical needs in autoimmune diseases and malignancies. | $2.5M | Corporate Round | Aug 05, 2025 |  |
| ENTEROME | Enterome is an integrated company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics.Enterome is focused on the identification of the bioactive molecules that are differentially expressed, secreted and regulated by the gut microbiome, whichplay a central role in the regulation of key aspects of human physiology and the immune system. | $19M | Venture - Series Unknown | Jun 12, 2025 |  |
| LTZ Therapeutics | LTZ develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need. | $40M | Series A | Apr 24, 2025 |  |
| Verismo Therapeutics | Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer. Verismo’s cellular therapy, known as KIR-CAR, is designed to provide a “natural stimulation” to T cells without triggering the T-cell exhaustion for the treatment of solid tumors. The lead therapy candidates inpreclinical development are targeting pancreatic cancer, mesothelioma, and ovarian cancer. | $4.1M | Seed | Jan 07, 2025 |  |
| PeproMene Bio | PeproMene Bio, Inc is an Irvine, California-based clinical-stage biotech startup. We are dedicated to the development of innovative therapeutics for cancer and immunological illnesses. Our CAR-T treatment concept for BAFFR is based on a new antibody that targets the B-cell Activating Factor Receptor (BAFF-R). | $5M | Corporate Round | Dec 18, 2024 |  |
| Innate Pharma | Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drug candidates for cancer and inflammatory diseases.The Company specializes in the development of novel monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led tolicensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb. | $7.9M | Post-IPO Equity | Dec 06, 2024 |  |
| Araris Biotech | Araris Biotech AG (Araris) is a biotechnology start-up company. Their aim is to deliver a breakthrough technology platform that enables the development of next-generation ADC-based safe and potent drugs for various diseases and ailments.They are committed to produce high quality ADCs that do not require any engineering (antibody and/orcell-line) for site-specific conjugation instead the antibodies can directly be taken 'off-the-shelf'. The site-specifically modified ADCs can thus be produced rapidly within a few days and quality control and analysis can be performed quickly with high confidence. Their ADC technology is backed by two patents. | $24M | Series A | Oct 04, 2022 |  |

7 of 7 investments shown.

## Co-investors
- [4BIO Capital](https://shizune.co/investors/profile/4bio-capital-partners) — VC Fund, 1 deal together
- [Primo Capital](https://shizune.co/investors/profile/barcamper-ventures) — VC Fund, 1 deal together
- [b2venture](https://shizune.co/investors/profile/btovpartners) — VC Fund, 1 deal together
- [GL Ventures LLC](https://shizune.co/investors/profile/gl-ventures-llc) — VC Fund, 1 deal together
- [Lanchi Ventures](https://shizune.co/investors/profile/lanchi-ventures) — VC Fund, 1 deal together
- [Lapam Capital](https://shizune.co/investors/profile/lapam-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Institute for Follicular Lymphoma Innovation invest in?

Institute for Follicular Lymphoma Innovation invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Corporate Round stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Institute for Follicular Lymphoma Innovation last invest?

The most recent investment recorded for Institute for Follicular Lymphoma Innovation closed in Aug 2025. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co